Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
Wainberg
M A
MA
Jewish General Hospital, Montreal, Canada.
Tremblay
M
M
Rooke
R
R
Blain
N
N
Soudeyns
H
H
Parniak
M A
MA
Yao
X J
XJ
Li
X G
XG
Fanning
M
M
Montaner
J S
JS
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D002170:Canada / Q000453:epidemiology; D002478:Cells, Cultured; D004352:Drug Resistance, Microbial / Q000235:genetics; D014644:Genetic Variation; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000382:microbiology; D008562:Membrane Glycoproteins / Q000378:metabolism; D009705:Nucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism*; D012680:Sensitivity and Specificity; D014759:Viral Envelope Proteins / Q000378:metabolism; D015215:Zidovudine / Q000494:pharmacology* / Q000627:therapeutic use
D008562:Membrane Glycoproteins; D009705:Nucleosides; D014759:Viral Envelope Proteins; D015215:Zidovudine; D012194:RNA-Directed DNA Polymerase